Adaptimmune Therapeutics Plc (ADAP)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Adaptimmune Therapeutics Plc (ADAP)
Company Performance

Current Price

as of Oct 18, 2024

$0.84

P/E Ratio

N/A

Market Cap

$215.52M

Description

Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Metrics

Overview

  • HQAbingdon, OX
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerADAP
  • Price$0.8427+0.14%

Trading Information

  • Market Cap$215.52M
  • Float88.51%
  • Average Daily Volume (1m)1,098,666
  • Average Daily Volume (3m)1,601,436
  • EPS-$0.34

Company

  • Revenue$141.56M
  • Rev Growth (1yr)2,394.41%
  • Net Income$69.60M
  • Gross Margin97.86%
  • EBITDA Margin53.87%
  • EBITDA$69.15M
  • EV$85.90M
  • EV/Revenue0.61
  • P/EN/A
  • P/S1.55
  • P/B2.24
Documents
SEC Filings
8-K (2024-09-23)
8-K (2024-08-12)
8-K (2024-08-02)
8-K (2024-07-16)
8-K (2024-06-11)
8-K (2024-05-30)
8-K (2024-05-15)
8-K (2024-05-14)
8-K (2024-04-12)
8-K (2024-03-06)
8-K (2024-02-27)
8-K (2024-02-16)
8-K (2024-01-31)
8-K (2024-01-04)
8-K (2023-12-06)
8-K (2023-11-14)
8-K (2023-11-08)
8-K (2023-11-03)
8-K (2023-10-31)
8-K (2023-08-31)
8-K (2023-08-09)
8-K (2023-06-29)
8-K (2023-06-01)
8-K (2023-05-30)
8-K (2023-05-22)
8-K (2023-05-16)
8-K (2023-05-12)
8-K (2023-04-11)
8-K (2023-03-10)
8-K (2023-03-06)
8-K (2023-02-16)
8-K (2023-01-31)
10-Q (2024-08-12)
10-Q (2024-05-15)
10-Q (2023-11-08)
10-Q (2023-08-09)
10-Q (2023-05-12)
10-K (2024-03-06)
10-K (2023-03-06)
Factset Street Account
Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO ($0.57, 0.00) (2023-10-23T08:36:03Z)
Adaptimmune Therapeutics reports Q3 EPS ($0.03) vs FactSet ($0.17) [5 est, ($0.22)-(0.14)] ($0.60, 0.00) (2023-11-08T12:33:28Z)
Adaptimmune selects ADP-600 as clinical candidate for best-in class PRAME strategy ($0.60, 0.00) (2023-11-08T12:10:05Z)
Adaptimmune receives transfer of IND for Lete-cel program ($0.45, 0.00) (2023-11-29T13:04:01Z)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report 2023Q4
Earnings Report (2023-11-08)
Earnings Report (2023-08-09)
Factset
Factset Business Description